Evidence map›Paper›PMID 37635436›Full record

ArticleAging2023

Correction for: CD229 interacts with RASAL3 to activate RAS/ERK pathway in multiple myeloma proliferation.

Zigen Lin, Xiaozhu Tang, Yuhao Cao, Lijin Yang, Mingmei Jiang, Xinying Li, Jie Min, Bing Chen, Ye Yang, Chunyan Gu

Open access · hybridAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Zigen LinDepartment of Hematology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Xiaozhu TangSchool of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
Yuhao CaoSchool of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
Lijin YangSchool of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
Mingmei JiangSchool of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
Xinying LiSchool of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
Jie MinSchool of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
Bing ChenDepartment of Hematology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Ye YangSchool of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
Chunyan GuDepartment of Hematology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Nanjing University of Chinese Medicine · CNNanjing Drum Tower Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CD229multiple myelomaRASRASAL3

Identifiers

PMID37635436
PMCPMC10496985
OpenAlexW4386209769

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.